Atossa Genetics is making moves!!

Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
This is what we are looking for, go long with this CV company. Find a good entry point and squat!! If FDA approved this will go back where it cam from $$$
Beyond Technical Analysis

Clause de non-responsabilité